ALCAM/CD166 is a TGF-b-responsive marker and functional regulator of prostate cancer metastasis to bone

Amanda G. Hansen, Shanna A. Arnold, Ming Jiang, Trenis D. Palmer, Tatiana Ketova, Alyssa Merkel, Michael Pickup, Susan Samaras, Yu Shyr, Harold L. Moses, Simon W. Hayward, Julie A. Sterling, Andries Zijlstra

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The dissemination of prostate cancer to bone is a common, incurable aspect of advanced disease. Prevention and treatment of this terminal phase of prostate cancer requires improved molecular understanding of the process as well as markers indicative of molecular progression. Through biochemical analyses and loss-of-function in vivo studies, we demonstrate that the cell adhesion molecule, activated leukocyte cell adhesion molecule (ALCAM), is actively shed from metastatic prostate cancer cells by the sheddase ADAM17 in response to TGF-b. Not only is this posttranslational modification of ALCAM a marker of prostate cancer progression, the molecule is also required for effective metastasis to bone. Biochemical analysis of prostate cancer cell lines reveals that ALCAM expression and shedding is elevated in response to TGF-b signaling. Both in vitro and in vivo shedding is mediated by ADAM17. Longitudinal analysis of circulating ALCAM in tumor-bearing mice revealed that shedding of tumor, but not host-derived ALCAM is elevated during growth of the cancer. Gene-specific knockdown of ALCAM in bone-metastatic PC3 cells greatly diminished both skeletal dissemination and tumor growth in bone. The reduced growth of ALCAM knockdown cells corresponded to an increase in apoptosis (caspase-3) and decreased proliferation (Ki67). Together, these data demonstrate that the ALCAM is both a functional regulator as well as marker of prostate cancer progression.

Original languageEnglish
Pages (from-to)1404-1415
Number of pages12
JournalCancer Research
Volume74
Issue number5
DOIs
Publication statusPublished - 2014 Mar 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'ALCAM/CD166 is a TGF-b-responsive marker and functional regulator of prostate cancer metastasis to bone'. Together they form a unique fingerprint.

  • Cite this

    Hansen, A. G., Arnold, S. A., Jiang, M., Palmer, T. D., Ketova, T., Merkel, A., Pickup, M., Samaras, S., Shyr, Y., Moses, H. L., Hayward, S. W., Sterling, J. A., & Zijlstra, A. (2014). ALCAM/CD166 is a TGF-b-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Research, 74(5), 1404-1415. https://doi.org/10.1158/0008-5472.CAN-13-1296